[25-NSE] Verona Pharma plc SEC Filing

Rhea-AI Filing Summary

Verona Pharma plc submitted a Form 25 notice relating to removal of a class of its securities from listing and/or registration on the Nasdaq Stock Market LLC. The filing identifies the issuer's principal office in London and cites the Exchange rules under 17 CFR 240.12d2-2 as the basis for the strike/withdrawal action, with checkboxes for the (a)(1)–(a)(4) provisions and references to subsections (b) and (c) about procedural compliance. The notice also shows the Commission File Number 001-38067 and the OMB approval number 3235-0080.

Positive

• Procedural compliance is documented under 17 CFR 240.12d2-2(b) and (c)
• Issuer identity and Exchange are clearly stated (Verona Pharma plc; Nasdaq)

Negative

• Delisting/withdrawal indicates the class of securities will be removed from Nasdaq, which can reduce liquidity
• No effective date or follow-up actions are provided in the filing text, leaving timing unclear

Insights

Exchange Listing Specialist

Form 25 notifies Nasdaq and SEC that a Verona Pharma security will be struck from Nasdaq listing.

The document records a formal removal/withdrawal action under 17 CFR 240.12d2-2, with compliance statements for both the Exchange and the issuer. This is an administrative notice to the SEC that listing/registration will end for the identified class of securities.

Key near-term effects are procedural: the security will no longer be listed on Nasdaq, which may affect market access and liquidity for holders. Watch for published effective dates of delisting, any parallel filings (e.g., Form 15) or transfer arrangements to another market within standard post-filing windows.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-38067

Issuer:	Verona Pharma plc
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	3 More London Riverside
	London	UNITED KINGDOM	SE1 2RE
Telephone number:					442,032,834,200

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

American Depositary Shares

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2025-10-07	By	Tara Petta		AVP
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.